PUBLISHER: SkyQuest | PRODUCT CODE: 1172471
PUBLISHER: SkyQuest | PRODUCT CODE: 1172471
Global Hyperphosphatemia Therapeutics Market was valued at USD 2.46 billion in 2021,and it is expected to reach USD 3.53 billion by 2028 at a CAGR of 5.3 % over the forecast period (2022-2028).
A condition called hyperphosphatemia is brought on by a high level of phosphate or phosphorous in the blood. The chemical phosphate, which contains the mineral phosphorous, is present in the body. The mineral phosphorus is crucial for the growth of teeth and bones as well as for converting food into body energy. The main locations of phosphate in the body are the teeth, bones, cells, and in very small quantities, the blood. The kidneys have a role in controlling the body's phosphate levels. However, a variety of issues or illnesses cause kidney damage, which results in a persistently high level of phosphate in the blood. People with end-stage kidney disease are more likely to develop hyperphosphatemia, which is very common in people with chronic kidney disease.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperphosphatemia Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hyperphosphatemia Therapeutics Market is segmented by Product Type, Distribution Channel, and Region. Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. Based on Distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
An important driver that is enhancing the prospects for new pharmaceutical interventions in the market for treating hyperphosphatemia is the increasing incidence of end-stage renal disease. The available management options suggest using an integrated strategy to lower high levels of calcium and phosphorus. The patient population's high risk of cardiovascular events has increased the need for a multidisciplinary approach to managing it, including treatment. The market for treating hyperphosphatemia appears to have an unmet need for products combining calcium acetate and magnesium. The new class of phosphate binders is of particular interest. Clinical trials that specifically focus on evaluating them for their effectiveness, tolerability, and safety in advanced chronic kidney disease are therefore urgently needed (CKD).
One of the main factors limiting the market's growth is poor treatment compliance among dialysis patients as a result of their heavy pill load. For instance, a dialysis patient is typically expected to take 10 to 12 different types of medications, according to a National Center for Biotechnology Information (NCBI) article. Nearly 80% of patients take four or more pills daily from phosphate binders, which can have negative side effects like gastrointestinal intolerance. Therefore, it is anticipated that these factors will limit the uptake of phosphate binders among CKD patients, thereby limiting the market's expansion.
It is very difficult to achieve ideal phosphate control in CKD patients receiving dialysis. The ability to control phosphate levels in dialysis patients has not significantly improved despite the extraordinary advancements in dialysis techniques over the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the introduction of new hyperphosphatemia therapeutics and updating the treatment guidelines in order to improve the treatment option for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3), which is currently being researched. By 2021, the drug is expected to go on sale.